Alnylam says united kingdom's mhra grants early access to lumasiran

Alnylam announces that the united kingdom’s mhra grants early access to lumasiran.alnylam pharmaceuticals inc - lumasiran indicated within eams for treatment of patients with ph1.alnylam pharmaceuticals - positive scientific opinion under eams to make lumasiran treatment available for uk ph1 patients before marketing authorization.alnylam pharmaceuticals - fda has granted a priority review for nda and has set an action date of dec. 3, under pdufa.
ALNY Ratings Summary
ALNY Quant Ranking